New York, Jan 5, 2026, 21:32 EST — Market closed
Thermo Fisher Scientific Inc shares rose 3.2% to close at $611.20 on Monday, after trading between $590 and $611.60 and hitting a fresh 52-week high. Evercore ISI lifted its price target — an analyst estimate for where a stock could trade — to $650 from $610 and kept an “Outperform” rating, meaning it expects the shares to beat the broader market. Marketscreener data showed a consensus “Buy” rating and an average target price of $641.57. marketwatch.com+2Moomoo+2
The rally comes as investors position ahead of late-January earnings and look for clarity on laboratory and drug-development spending into 2026. Thermo Fisher said it will release fourth-quarter and full-year 2025 results before the market opens on Jan. 29 and hold a conference call at 8:30 a.m. ET.
Life-sciences tools companies sell lab instruments, diagnostics and consumables. Their outlook often tracks research budgets at pharmaceutical and biotech companies, so traders watch Thermo’s guidance for read-across to peers.
Peers also advanced on Monday. Danaher gained 2.2%, while Agilent Technologies rose 3.6% and Illumina climbed 5.2%, underscoring a stronger tape for the group.
The broader market backdrop was supportive, with Wall Street ending higher and the Dow closing at an all-time peak. The S&P 500 rose 0.64% and the Nasdaq added 0.69%, according to Reuters.
Thermo Fisher is also heading into earnings with a major deal in view: its agreement to buy clinical services provider Clario for up to $9.4 billion, expected to close in early 2026. Leerink Partners analyst Puneet Souda said the deal expands Thermo’s reach into clinical development, a “more steadily growing and attractive area” than early-stage research. Reuters
In its last quarterly update in October, Thermo raised annual profit and revenue forecasts on robust demand for lab tools and benefits from recent acquisitions, while pointing to a decline in China. It said revenue from China would be down by a mid-to-high single-digit percentage because of a government bulk-buying program for medical devices at sharp discounts.
After Monday’s breakout, the $610 area is an immediate test; a move back below it would put the $590 region from Monday’s lows back on the radar. The bigger risk is a cautious tone on customer spending or margins on Jan. 29, when expectations are rising into the print.
Beyond company results, traders are eyeing the U.S. employment report for December on Jan. 9 and the December CPI report on Jan. 13, both due at 8:30 a.m. ET. Thermo Fisher’s Jan. 29 results remain the next major catalyst for TMO.
